2023
Leveraging GWAS data derived from a large cooperative group trial to assess the risk of taxane-induced peripheral neuropathy (TIPN) in patients being treated for breast cancer: Part 2—functional implications of a SNP cluster associated with TIPN risk in patients being treated for breast cancer
Lustberg M, Wu X, Fernández-Martínez J, de Andrés-Galiana E, Philips S, Leibowitz J, Schneider B, Sonis S. Leveraging GWAS data derived from a large cooperative group trial to assess the risk of taxane-induced peripheral neuropathy (TIPN) in patients being treated for breast cancer: Part 2—functional implications of a SNP cluster associated with TIPN risk in patients being treated for breast cancer. Supportive Care In Cancer 2023, 31: 178. PMID: 36809570, PMCID: PMC11344472, DOI: 10.1007/s00520-023-07617-6.Peer-Reviewed Original ResearchConceptsGWAS dataSNP clustersFunctional analysisGO termsNon-protein coding genesGene Ontology termsGene Set Enrichment AnalysisCluster of SNPsNervous system developmentCoding genesRetinoic acid bindingOntology termsProtein kinase C bindingEnrichment analysisMetabolic processesGenesAcid bindingGlycosyltransferase activitySNPsPathological implicationsGWASC bindingGene signaturePhenotypeTransferase activity
2010
Epigenetic Therapy in Breast Cancer
Lustberg M, Ramaswamy B. Epigenetic Therapy in Breast Cancer. Current Breast Cancer Reports 2010, 3: 34-43. PMID: 23097683, PMCID: PMC3477864, DOI: 10.1007/s12609-010-0034-0.Peer-Reviewed Original ResearchEpigenetic changesHistone deacetylase inhibitorsMajor epigenetic changesNucleosome remodelingHistone modificationsEpigenetic regulationEpigenetic mechanismsDNA methylationGene sequencesEpigenetic therapyGene expressionDemethylating agentDeacetylase inhibitorsMultistep processBreast cancerEpigeneticsBreast carcinogenesisGenesMethylationSystemic therapyClinical trialsEffective therapyReversible processRegulationSingle agent
2009
Epigenetic targeting in breast cancer: therapeutic impact and future direction.
Lustberg M, Ramaswamy B. Epigenetic targeting in breast cancer: therapeutic impact and future direction. Drug News & Perspectives 2009, 22: 369-81. PMID: 19890494, PMCID: PMC3658161, DOI: 10.1358/dnp.2009.22.7.1405072.Peer-Reviewed Original ResearchConceptsEpigenetic changesHistone modificationsHistone deacetylase inhibitorsGene expressionMajor epigenetic changesHeritable changesRepressor complexDNA methylationGene sequencesEpigenetic targetingDeacetylase inhibitorsMultistep processMethylationExpressionEpigeneticsBreast carcinogenesisGenesReversible processAntiapoptosisNovel therapiesSequenceInvasionProliferationTargetingBreast cancer